A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

References

• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-S14
   Google Scholar
• International Association for the Study of Pain (IASP). IASP Taxonomy. 2015. http://www.iasp-pain.org/Taxonomy#Neuropathicpain. Last Accessed: August 17, 2015
   Google Scholar
• de Salas-Cansado M, Perez C, Saldana MT, et al. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain. Pain Med 2012;13:699-710
   PubMed Web of Science ®Google Scholar
• Gordon J, Lister S, Prettyjohns M, et al. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ 2012;15:207-18
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). NICE guideline CG173: Neuropathic pain - pharmacological management. 2013. http://guidance.nice.org.uk/CG173/NICEGuidance/pdf/English. Last Accessed August 17, 2015
   Google Scholar
• Doth AH, Hansson PT, Jensen MP, et al. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010;149:338-44
   PubMed Web of Science ®Google Scholar
• Taylor RS, Jensen M, Doth AH. PSY36 The health burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Value Health 2009;12:A136-7
   Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
   PubMed Web of Science ®Google Scholar
• McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127-35
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
   PubMed Web of Science ®Google Scholar
• Closs SJ, Staples V, Reid I, et al. Managing the symptoms of neuropathic pain: an exploration of patients' experiences. J Pain Symptom Manage 2007;34:422-33
   PubMed Web of Science ®Google Scholar
• Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356-63
   PubMed Web of Science ®Google Scholar
• Breivik H, Eisenberg E, O'Brien T, Openminds. The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health 2013;13:1229
   PubMed Web of Science ®Google Scholar
• Eldessouki R, Dix Smith M. Health care system information sharing: a step toward better health globally. Value Health Regional Issues 2012;1:118-20
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. 2013. http://publications.nice.org.uk/pmg9. Last Accessed August 17, 2015
   Google Scholar
• Annemans L, Caekelbergh K, Morlion B, et al. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg 2008;63:170-8
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Malone DC, McCarberg B, et al. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin 2011;27:939-50
   PubMed Web of Science ®Google Scholar
• Beard SM, McCrink L, Le TK, et al. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin 2008;24:385-99
   PubMed Web of Science ®Google Scholar
• Bellows BK, Dahal A, Jiao T, et al. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J Pain Palliat Care Pharmacother 2012;26:153-64
   PubMedGoogle Scholar
• Carlos F, Ramirez-Gamez J, Duenas H, et al. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico. J Med Econ 2012;15:233-44
   PubMedGoogle Scholar
• Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain 2006;7:119-28
   PubMed Web of Science ®Google Scholar
• O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 2007;55:1176-84
   PubMed Web of Science ®Google Scholar
• O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics 2008;26:1045-64
   PubMed Web of Science ®Google Scholar
• Dakin H, Nuijten M, Liedgens H, et al. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom. Clin Ther 2007;29:1491-507
   PubMed Web of Science ®Google Scholar
• Ritchie M, Liedgens H, Nuijten M. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis. Clin Drug Investig 2010;30:71-87
   PubMed Web of Science ®Google Scholar
• Rodriguez MJ, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-96
   PubMed Web of Science ®Google Scholar
• Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006;28:1922-34
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• de Salas-Cansado M, Perez C, Saldana MT, et al. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes 2012;6:303-12
   PubMed Web of Science ®Google Scholar
• Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis. J Pain 2007;8:396-404
   PubMed Web of Science ®Google Scholar
• Athanasakis K, Petrakis I, Karampli E, et al. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. BMC Neurol 2013;13:56
   PubMed Web of Science ®Google Scholar
• Chevalier P, Lamotte M, Van Campenhout H, et al. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium. J Med Econ 2013;16:596-605
   PubMedGoogle Scholar
• Prettyjohns M, Sandelin R, Lister S, et al. A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting. J Med Econ 2012;15:1097-109
   PubMedGoogle Scholar
• Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006;15:1295-310
   PubMed Web of Science ®Google Scholar
• Mundipharma International Ltd. Patient journey – Neuropathic pain. 2015
   Google Scholar
• EMC. Summary of Product Characteristics; Lyrica Capsules. 2015. http://www.medicines.org.uk/EMC/medicine/14651/SPC/Lyrica+Capsules/#POSOLOGY. Accessed August 26, 2015
   Google Scholar
• EMC. SPC; Cymbalta 30mg hard gastro-resistant capsules, Cymbalta 60mg hard gastro-resistant capsules. 2015. https://www.medicines.org.uk/emc/medicine/15694. Accessed October 26, 2015
   Google Scholar
• O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122(10Suppl):S22-S32
   Google Scholar
• Jensen MP. The Validity and Reliability of Pain Measures for use in Clinical Trials in Adults: Review Paper Written for the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). Washington, DC, : Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), 2003
   Google Scholar
• Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63(11Suppl):S240-S52
   Google Scholar
• Rycroft CE, Hirst M, Dunlop WC, et al. the suitability of end point designs for health technology assessment in chronic pain studies. Value Health 2015;18:987-93
   PubMed Web of Science ®Google Scholar
• Longworth L, Rowen, D. NICE DSU: Technical Support Document 10: the use of mapping methods to estimate health state utility values. Decision Support Unit, ScHARR, University of Sheffield, 2011. p 31
   Google Scholar
• Cornelius VR, Sauzet O, Williams JE, et al. Adverse event reporting in randomised controlled trials of neuropathic pain: considerations for future practice. Pain 2013;154:213-20
   PubMed Web of Science ®Google Scholar
• Shukralla AA, Tudur-Smith C, Powell GA, et al. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res 2011;97:20-9
   PubMed Web of Science ®Google Scholar
• Sullivan W, Hirst M, Beard S, et al. Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. Eur J Health Econ 2016;17:755-70
   PubMed Web of Science ®Google Scholar
• Sullivan W, Payne K. The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose. Pharmacoeconomics 2011;29:455-9
   PubMed Web of Science ®Google Scholar
• Immpact. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. 2016. http://www.immpact.org/. Accessed February 10, 2016
   Google Scholar
• Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:355-71
   PubMed Web of Science ®Google Scholar